Low molecular weight heparin and 28-day mortality among patients with coronavirus disease 2019: A cohort study in the early epidemic era

Wei Qin; Fen Dong; Zhu Zhang; Bingzhu Hu; Shi Chen; Ziyang Zhu; Fajiu Li; Xiaojiang Wang; Yunxia Zhang; Yimin Wang; Kaiyuan Zhen; Jing Wang; Ismaïl Elalamy; Chenghong Li; Zhenguo Zhai; Bruce L Davidson; Chen Wang

doi:10.1016/j.thromres.2020.11.020

Low molecular weight heparin and 28-day mortality among patients with coronavirus disease 2019: A cohort study in the early epidemic era

Thromb Res. 2021 Feb:198:19-22. doi: 10.1016/j.thromres.2020.11.020. Epub 2020 Nov 23.

Authors

Wei Qin¹, Fen Dong², Zhu Zhang³, Bingzhu Hu¹, Shi Chen¹, Ziyang Zhu¹, Fajiu Li¹, Xiaojiang Wang¹, Yunxia Zhang³, Yimin Wang³, Kaiyuan Zhen³, Jing Wang⁴, Ismaïl Elalamy⁵, Chenghong Li⁶, Zhenguo Zhai⁷, Bruce L Davidson⁸, Chen Wang⁹

Affiliations

¹ Department of Pulmonary and Critical Care Medicine, Affiliated Hospital of Jianghan University, No.168 Hongkong Road, Jiang'an District, Wuhan City, Hubei Province 430000, China.
² Institute of Clinical Medical Sciences, China-Japan Friendship Hospital, Beijing, China.
³ Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, China; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, China; National Clinical Research Center for Respiratory Diseases, China.
⁴ Institute of Basic Research, Chinese Academy of Medical Sciences, China.
⁵ Hematology and Thrombosis Center, Tenon University Hospital, INSERM UMRS 938, Sorbonne University, Paris, France; The First I.M. Sechenov Moscow State Medical University, Moscow, Russia.
⁶ Department of Pulmonary and Critical Care Medicine, Affiliated Hospital of Jianghan University, No.168 Hongkong Road, Jiang'an District, Wuhan City, Hubei Province 430000, China. Electronic address: 15827636399@163.com.
⁷ Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, China; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, China; National Clinical Research Center for Respiratory Diseases, China. Electronic address: zhaizhenguo2011@126.com.
⁸ Division of Pulmonary and Critical Care Medicine, Providence Health System, Seattle, WA, United States of America.
⁹ Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, China; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, China; National Clinical Research Center for Respiratory Diseases, China; Peking Union Medical College, Chinese Academy of Medical Sciences, China.

No abstract available

Publication types

Letter
Observational Study
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Aged, 80 and over
Anticoagulants / therapeutic use*
COVID-19 / blood
COVID-19 / mortality
COVID-19 Drug Treatment*
China / epidemiology
Female
Hemorrhage / chemically induced
Heparin, Low-Molecular-Weight / therapeutic use*
Hospital Mortality
Hospitalization
Humans
Male
Middle Aged
Risk Factors
Time Factors
Treatment Outcome

Substances

Anticoagulants
Heparin, Low-Molecular-Weight